Group 1 - Brendan completed a Ph.D. at Stanford University in organic synthesis in 2009 [1] - He worked for Merck from 2009 to 2013 and has experience in biotech startups such as Theravance and Aspira [1] - Brendan is a co-founder of 1200 Pharma, which spun out of Caltech and received significant investment in the 8 figures [1] Group 2 - Brendan remains an avid investor focused on market trends, particularly in biotechnology stocks [1]

Core Insights - Ionis Pharmaceuticals reported better-than-expected revenue and a smaller-than-expected loss for Q4 2024, indicating strong operational performance [2][6]. Financial Performance - Q4 2024 revenue reached $227 million, significantly exceeding analysts' expectations of $135 million, marking a 68.1% increase [3][6]. - The earnings loss was $0.66 per share, which was better than the anticipated loss of $1.11 per share, reflecting effective operational execution [3][7]. - Total revenue decreased by 30.2% compared to Q4 2023, where it was $325 million [3]. Operational Highlights - Ionis' non-GAAP operating expenses were $301 million, a slight decrease of 1.3% from the previous year [3][7]. - The successful launch of Wainua contributed to the positive revenue surprise, while royalty revenue from Spinraza remained a significant revenue source [6][7]. Strategic Focus - The company is expanding its drug offerings and enhancing the reach of its marketed medicines, with a focus on collaborations to mitigate development risks [5][8]. - Ionis has formed strategic alliances with Theratechnologies and Otsuka, which have provided financial support through milestones and royalties [8]. Future Outlook - Ionis anticipates revenue exceeding $600 million in 2025, with a planned operating loss of less than $495 million [9]. - The company has cash reserves of $2.3 billion, which will support continued investments in product launches and R&D [9]. - Three independent product launches are planned for the year, including donidalorsen for hereditary angioedema [10].

YE:2024 Business Update and Financial Results February 19, 2025 Nasdaq: IONS 1 On Today's Earnings Call Beth Hougen Chief Financial Officer 2 Brett Monia, Ph.D. Chief Executive Officer Kyle Jenne Chief Global Product Strategy Officer Richard Geary, Ph.D. Chief Development Officer Eric Swayze, Ph.D. Executive Vice President, Research Forward-Looking Statements This presentation includes forward-looking statements regarding our business, financial guidance and the therapeutic and commercial potential of our c ...

On Wednesday, Ionis Pharmaceuticals Inc IONS reported a fourth-quarter EPS loss of $0.66, up from a loss of $0.06, beating the consensus of a $1.10 loss.The company reported an adjusted net loss of $68 million versus a net income of $17 million.Ionis reported quarterly sales of $227 million, down from $325 million a year ago, beating the consensus of $137.6 million.Ionis says 2024 revenue of $705 million exceeded guidance as the company continued to generate revenue from diverse sources. The company added n ...

Exhibit 99.1 Ionis reports fourth quarter and full year 2024 financial results - First independent launch underway following TRYNGOLZATM approval - - Second independent launch on track with donidalorsen PDUFA August 21, 2025 - - WAINUATM U.S. launch delivering accelerating sequential growth - - Ionis exceeds 2024 financial guidance and provides full year 2025 guidance - CARLSBAD, Calif., February 19, 2025 – Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the "Company") today reported financial results for the f ...

For the quarter ended December 2024, Ionis Pharmaceuticals (IONS) reported revenue of $227 million, down 30.2% over the same period last year. EPS came in at -$0.66, compared to -$0.06 in the year-ago quarter.The reported revenue represents a surprise of +65.19% over the Zacks Consensus Estimate of $137.42 million. With the consensus EPS estimate being -$1.12, the EPS surprise was +41.07%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectation ...

Core Viewpoint - Ionis Pharmaceuticals is expected to report a significant quarterly loss and a substantial decline in revenues compared to the previous year [1] Financial Performance - Analysts predict a quarterly loss of $1.12 per share, reflecting a decline of 1766.7% year-over-year [1] - Revenues are forecasted to be $137.47 million, representing a year-over-year decrease of 57.7% [1] Earnings Estimates Revisions - Over the last 30 days, there has been an upward revision of 3.7% in the consensus EPS estimate for the quarter [2] - Revisions to earnings estimates are crucial indicators for predicting potential investor actions regarding the stock [3] Revenue Breakdown - Revenue from Spinraza royalties is estimated to reach $60.73 million, indicating a year-over-year change of -2% [5] - Licensing and royalty revenue is projected at $5.23 million, reflecting a year-over-year change of -34.7% [5] - Total commercial revenue is estimated at $80.55 million, showing a change of +2% from the prior-year quarter [6] - Revenue from Tegsedi and Waylivra is expected to be $7.06 million, indicating a change of -21.6% from the prior-year quarter [6] - Collaborative agreement revenue is projected at $43.79 million, reflecting a year-over-year change of -75.5% [7] Market Performance - Shares of Ionis Pharmaceuticals have experienced a change of -1.2% in the past month, compared to a +4.7% move of the Zacks S&P 500 composite [7] - The company holds a Zacks Rank 3 (Hold), indicating it is expected to mirror overall market performance in the near future [7]

– Accelerating value creation with numerous commercial, regulatory and pipeline milestones –– Ionis outlines clear path to sustained positive cash flow –CARLSBAD, Calif., Jan. 13, 2025 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced highlights from the Company's 2024 achievements and previewed important milestones expected in 2025. Ionis will provide a business update at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15 at 10:30am PT; the presentation is a ...

Portfolio Updates and Anticipated Milestones - Praxis has three blockbuster programs in late-stage development, with potential for four product launches between 2026 and 2028 [1] - The Essential3 program for ulixacaltamide in essential tremor (ET) includes two Phase 3 studies, with over 100,000 patients showing interest in participating since recruitment began in November 2023 [2] - Relutrigine is being evaluated in the EMBOLD study for developmental and epileptic encephalopathies (DEEs), with plans for the EMERALD study in a broader patient population [3] - Praxis shared an update at the 2024 AES Annual Meeting for an emergency use patient who achieved extended benefit after receiving relutrigine [4] - Ulixacaltamide is a highly selective small molecule inhibitor of T-type calcium channels, currently in late-stage development for essential tremor [5] - Praxis has completed discussions with global regulatory agencies to harmonize a registrational study design for elsunersen, with trial design and timelines expected in Q1 2025 [6] - UCB exercised its option to in-license global development and commercialization rights for a KCNT1 small molecule candidate, with Praxis eligible for up to $100 million in milestone payments and tiered royalties [6] - Praxis is on track to nominate development candidates for its early-stage ASO therapeutic initiatives in 2025, including PRAX-080, PRAX-090, and PRAX-100 [6] Clinical Trial Progress and Results - Vormatrigine demonstrated strong competitive differentiation in Phase 1 studies, with full results to be shared at an upcoming medical conference [10] - The EMPOWER observational study has enrolled over 2,000 patients, with early results shared at the 2024 AES Annual Meeting [10] - The RADIANT Phase 2 study for focal onset seizures (FOS) and generalized epilepsy is enrolling patients, with topline results expected in H1 2025 [10] - The POWER1 Phase 2/3 registrational study for treatment-resistant FOS is progressing, with topline results anticipated in H2 2025 [10] - Relutrigine showed a 46% placebo-adjusted reduction in monthly motor seizures in the EMBOLD study, with 77% reduction in motor seizures for patients continuing into the open-label extension [17] - Over 30% of patients achieved seizure freedom status while on relutrigine, with a median of 46 days of seizure freedom compared to 3 days at baseline [17] Regulatory and Commercial Developments - Praxis anticipates filing the NDA for ulixacaltamide in 2025, following positive results from the Essential3 program [9] - The company plans to re-initiate a study of ulixacaltamide in Parkinson's disease, addressing unmet needs for non-dopaminergic treatment options [9] - Praxis received a third rare pediatric drug designation (RPDD) for relutrigine in Dravet Syndrome, in addition to previous designations for SCN2A and SCN8A DEEs [17] - The company expects to initiate the pivotal trial for elsunersen in H1 2025, following regulatory feedback [8] Financial and Strategic Outlook - Praxis has a cash and investment position of approximately $470 million at the end of 2024, supporting a runway into 2028 [15] - The company is well-positioned for a readout-rich 2025, with results anticipated for ulixacaltamide, vormatrigine, and relutrigine, as well as regulatory submissions [8] - Praxis plans to provide a thorough update across its portfolio at the Investor R&D Day in Q2 2025 [8]

CARLSBAD, Calif., Jan. 8, 2025 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P. Monia, Ph.D., chief executive officer, will present a company overview at the 43rd Annual J.P. Morgan Healthcare Conference at 10:30 a.m. PT on Wednesday, January 15, 2025. A live webcast of the presentation can be accessed on the Investors & Media section of the Ionis website at https://ir.ionis.com/events. A replay will be available on the Ionis website within 48 hours and will be archiv ...